SOL-GEL TECHNOLOGIES LTD
SLGLNASDAQTrading Snapshot
- Day Range
- $76.97 – $78.35
- 52-Week Range
- $14.78 – $97.97
- Volume
- $2.42B
- Avg Volume
- $1.90B
- Shares Outstanding
- 3.3M
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $108,000
- P/E Ratio
- -229.2
- P/S Ratio
- 13.8x
- EPS (TTM)
- $-0.37
- Dividend Yield
- 0.00%
Why Investors Own SLGL
- ✓High-growth profile — revenue up +23.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SOL-GEL TECHNOLOGIES LTD
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.